Established in 1998, went public in May 2012, Dongcheng Biochemicals Co.,Ltd has developed into an enterprise group which combines pharmaceutical R&D, production, marketing and capital operation together,across field of biochemical API, chemical synthetic drugs and modern Chinese Medicines. At present, DCB owns four subsidiaries, including – YanTai DongCheng Beifang Pharmaceuticals Co.,Ltd, YanTai DongCheng Dayang Pharmaceuticals Co.,Ltd , Yinan DongCheng Don gyuan Bioengineering Co.,Ltd and DongCheng Biochemicals (USA),Inc, also sets up R&D branch in Beijing and Shanghai. Currently, the number of DCB employee is reaching 1000 .    
      DCB now is one of the biggest biochemical API manufacturers in China, With leading production technology, reliable product quality and excellent international qualification background, the company’s Heparin sodium and Chondroitin Sulfate products have hold important place in global market . Currently 90% of DCB API products are for export, thanks to company’s well-established global sales network, our API products have been exported to more than fifty countries and regions, including USA,Germany,Austria, Japan etc.  Meanwhile, with strategic development approach of “Organic Growth, Coupled with M&A and integration”, DCB group also focuses on development of finished preparation, currently DCB’s finished preparations cover therapeutic area of Cardiovascular, oncology, orthopaedics, and anti-infection etc.
 
      Adhering to the concept of “Innovation, scientific development”, DCB is committed to innovation, and continuously increases technical and scientific research input. In Sep 2013, the new R&D and Quality Control center which DCB invested nearly 100million RMB has officially open.  Meanwhile, not only the company has set up a  R&D team consisted of professionals with strong academic and senior professional background, also brought together domestic experts、well-known universities and scientific research institutes to carry out all-round cooperation, therefore to provide power for company’s core competitiveness building and sustainable development.
 
      Care for life with sincerity, Continuous innovation, striving for perfection! In the future, DCB will carry on the mission of serving human health, implement “Organic growth, M&A and integration” development strategy, continuously integrate resources, improve product structure and ability of innovation, build company’s core competitiveness, to build a world class pharmaceutical enterprise.